Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Linifanib + Carboplatin/Paclitaxel in Advanced NSCLC
NCT00716534Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Jun 2008
- Primary completion
- Apr 2012
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 2, randomised, double-blind trial of linifanib in non-small cell lung cancer (NSCLC) (3 arms), sponsored by AbbVie Inc. Primary endpoint: Progression Free Survival. Started Jun 2008; status: completed.
02
Drugs
linifanib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00716534.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00716534.